{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:21:32Z","timestamp":1791580892592,"version":"4.3.4"},"reference-count":80,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.tranon.2020.100926","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T16:45:34Z","timestamp":1604421934000},"page":"100926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8549-326X","authenticated-orcid":false,"given":"Tristan","family":"Rupp","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5120-7680","authenticated-orcid":false,"given":"Oc\u00e9ane","family":"Pelouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1960-1506","authenticated-orcid":false,"given":"Laurie","family":"Genest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-6433","authenticated-orcid":false,"given":"Christophe","family":"Legrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Froget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8728-2922","authenticated-orcid":false,"given":"Vincent","family":"Castagn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2020.100926_bib0001","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1093\/annonc\/mdy192","article-title":"4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)\u2020","volume":"29","author":"Cardoso","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0002","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.tranon.2020.100926_bib0003","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0004","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1111\/cas.13802","article-title":"The role of sphingosine\u20101\u2010phosphate in inflammation and cancer progression","volume":"109","author":"Nagahashi","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.tranon.2020.100926_bib0005","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2875","article-title":"Sphingosine 1-phosphate and cancer","volume":"10","author":"Pyne","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0006","doi-asserted-by":"crossref","first-page":"18095","DOI":"10.18632\/oncotarget.7741","article-title":"Serum sphingolipidomic analyses reveal an upregulation of C16- ceramide and sphingosine-1-phosphate in hepatocellular carcinoma","volume":"7","author":"Grammatikos","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0007","doi-asserted-by":"crossref","first-page":"63324","DOI":"10.18632\/oncotarget.11450","article-title":"Sphingosine-1-phosphate induced epithelial-mesenchymal transition of hepatocellular carcinoma via an MMP-7\/syndecan-1\/TGF-\u03b2 autocrine loop","volume":"7","author":"Zeng","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0008","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-29144-9","article-title":"Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis","volume":"8","author":"Hirose","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2020.100926_bib0009","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jss.2016.05.022","article-title":"High levels of sphingolipids in human breast cancer","volume":"204","author":"Nagahashi","year":"2016","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0010","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.12659\/MSM.905833","article-title":"Triple negative breast cancer depends on sphingosine kinase 1 (SphK1)\/sphingosine-1-phosphate (S1P)\/sphingosine 1-phosphate receptor 3 (S1PR3)\/notch signaling for metastasis","volume":"24","author":"Wang","year":"2018","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.tranon.2020.100926_bib0011","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41582-018-0082-z","article-title":"Treatment of multiple sclerosis \u2014 success from bench to bedside","volume":"15","author":"Tintore","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.tranon.2020.100926_bib0012","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbior.2017.10.005","article-title":"Sphingosine kinase 1 in breast cancer","volume":"67","author":"Geffken","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.tranon.2020.100926_bib0013","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jcmm.12635","article-title":"The antineoplastic properties of FTY720: evidence for the repurposing of Fingolimod","volume":"19","author":"Patmanathan","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.tranon.2020.100926_bib0014","doi-asserted-by":"crossref","first-page":"23106","DOI":"10.18632\/oncotarget.7145","article-title":"The emerging role of FTY720 (Fingolimod) in cancer treatment","volume":"7","author":"White","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0015","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1158\/1078-0432.CCR-12-1050","article-title":"Sphingosine kinase 1 overexpression contributes to cetuximab resistance in human colorectal cancer models","volume":"19","author":"Rosa","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0016","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1158\/1535-7163.MCT-05-0021","article-title":"Effects of a novel immunomodulating agent, FTY720, on tumor growth and angiogenesis in hepatocellular carcinoma","volume":"4","author":"Ho","year":"2005","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2020.100926_bib0017","doi-asserted-by":"crossref","first-page":"8651","DOI":"10.1158\/0008-5472.CAN-10-1388","article-title":"FTY720 (Fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1","volume":"70","author":"Pchejetski","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0018","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1158\/1535-7163.MCT-16-0167","article-title":"FTY720 (Fingolimod) inhibits HIF1 and HIF2 signaling, promotes vascular remodeling, and chemosensitizes in renal cell carcinoma animal model","volume":"15","author":"Gstalder","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tranon.2020.100926_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1158\/0008-5472.CAN-05-2001","article-title":"Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization","volume":"66","author":"LaMontagne","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0020","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.18632\/oncotarget.2470","article-title":"AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients","volume":"5","author":"Langlois","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0021","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1016\/j.celrep.2016.11.012","article-title":"Tenascin-C orchestrates glioblastoma angiogenesis by modulation of pro- and anti-angiogenic signaling","volume":"17","author":"Rupp","year":"2016","journal-title":"Cell Rep."},{"key":"10.1016\/j.tranon.2020.100926_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1530\/ERC-16-0050","article-title":"FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion","volume":"23","author":"Kalhori","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0023","first-page":"1410","article-title":"Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models","volume":"62","author":"Azuma","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0024","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s10549-011-1903-6","article-title":"Fingolimod potentiates the effects of sunitinib malate in a rat breast cancer model","volume":"134","author":"Mousseau","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.tranon.2020.100926_bib0025","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","article-title":"Targeting the SphK1\/S1P\/S1PR1 axis that links obesity, chronic inflammation, and breast cancer metastasis","volume":"78","author":"Nagahashi","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0026","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.7150\/jca.18457","article-title":"Breast cancer cell line classification and its relevance with breast tumor subtyping","volume":"8","author":"Dai","year":"2017","journal-title":"J. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0027","first-page":"19","article-title":"Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade","author":"Martin","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0028","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.18632\/oncotarget.2741","article-title":"Silencing of CXCR4 sensitizes triple-negative breast cancer cells to cisplatin","volume":"6","author":"Liang","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0029","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-019-1689-8","article-title":"ATR mediates cisplatin resistance in 3D-cultured breast cancer cells via translesion DNA synthesis modulation","volume":"10","author":"Gomes","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.tranon.2020.100926_bib0030","doi-asserted-by":"crossref","first-page":"797","DOI":"10.4161\/cbt.28556","article-title":"Sphingosine analog fingolimod (FTY720) increases radiation sensitivity of human breast cancer cells in vitro","volume":"15","author":"Marvaso","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.tranon.2020.100926_bib0031","doi-asserted-by":"crossref","DOI":"10.1186\/s12885-015-1170-8","article-title":"Dose-response relationship in cisplatin-treated breast cancer xenografts monitored with dynamic contrast-enhanced ultrasound","volume":"15","author":"Chen","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0032","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1158\/0008-5472.967.65.3","article-title":"Silencing of CXCR4 Blocks Breast Cancer Metastasis","volume":"65","author":"Liang","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0033","doi-asserted-by":"crossref","first-page":"11614","DOI":"10.18632\/oncotarget.3426","article-title":"FTY720 enhances TRAIL-mediated apoptosis by up-regulating DR5 and down-regulating Mcl-1 in cancer cells","volume":"6","author":"Woo","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tranon.2020.100926_bib0034","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/0008-5472.CAN-11-2167","article-title":"Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis","volume":"72","author":"Nagahashi","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0035","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1186\/s12885-019-6278-9","article-title":"Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance","volume":"19","author":"Hill","year":"2019","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0036","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S1470-2045(15)70064-1","article-title":"Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial","volume":"16","author":"Hu","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0037","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/emmm.201202006","article-title":"Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours","volume":"5","author":"Park","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.tranon.2020.100926_bib0038","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7150\/thno.13515","article-title":"Triple-layered pH-responsive micelleplexes loaded with siRNA and cisplatin prodrug for NF-Kappa B targeted treatment of metastatic breast cancer","volume":"6","author":"Yu","year":"2016","journal-title":"Theranostics"},{"key":"10.1016\/j.tranon.2020.100926_bib0039","doi-asserted-by":"crossref","first-page":"19103","DOI":"10.1038\/srep19103","article-title":"3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained","volume":"6","author":"Zanoni","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2020.100926_bib0040","doi-asserted-by":"crossref","first-page":"507","DOI":"10.7150\/jca.2.507","article-title":"Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy","volume":"2","author":"Phung","year":"2011","journal-title":"J. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ddtec.2017.03.002","article-title":"The production of 3D tumor spheroids for cancer drug discovery","volume":"23","author":"Sant","year":"2017","journal-title":"Drug Discov. Today Technol."},{"key":"10.1016\/j.tranon.2020.100926_bib0042","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90874","article-title":"Prevention of breast cancer skeletal metastases with parathyroid hormone","volume":"2","author":"Swami","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.tranon.2020.100926_bib0043","first-page":"4641","article-title":"Surgically-induced multi-organ metastasis in an orthotopic syngeneic imageable model of 4T1 murine breast cancer","volume":"35","author":"Zhang","year":"2015","journal-title":"Anticancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0044","first-page":"165","article-title":"Metastasis inhibition in breast cancer by targeting cancer cell extravasation","volume":"11","author":"Cominetti","year":"2019","journal-title":"Breast Cancer (Dove Med Press)"},{"key":"10.1016\/j.tranon.2020.100926_bib0045","article-title":"Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: exploratory analysis of the GIM2 trial","author":"Lambertini","year":"2019","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0046","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jss.2016.06.022","article-title":"Breast cancer S1P is associated with pSphK1 and lymphatic metastasis","volume":"205","author":"Tsuchida","year":"2016","journal-title":"J. Surg. Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0047","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.canlet.2018.08.015","article-title":"FTY720 enhances the anti-tumor activity of carboplatin and tamoxifen in a patient-derived xenograft model of ovarian cancer","volume":"436","author":"Kreitzburg","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2020.100926_bib0048","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214469","article-title":"PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells","volume":"14","author":"Stafman","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100926_bib0049","first-page":"375","article-title":"Marked suppression of tumor growth by FTY720 in a rat liver tumor model: the significance of down-regulation of cell survival Akt pathway","volume":"30","author":"Ng","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0050","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2020.100926_bib0051","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"0","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tranon.2020.100926_bib0052","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-25263-5","article-title":"FTY720 decreases tumorigenesis in group 3 medulloblastoma patient-derived xenografts","volume":"8","author":"Garner","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.tranon.2020.100926_bib0053","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.imbio.2018.07.009","article-title":"Inhibition of RhoA and mTORC2\/Rictor by Fingolimod (FTY720) induces p21-activated kinase 1, PAK-1 and amplifies podosomes in mouse peritoneal macrophages","volume":"223","author":"Chen","year":"2018","journal-title":"Immunobiology"},{"key":"10.1016\/j.tranon.2020.100926_bib0054","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.canlet.2005.02.039","article-title":"FTY720, a fungus metabolite, inhibits invasion ability of androgen-independent prostate cancer cells through inactivation of RhoA-GTPase","volume":"233","author":"Zhou","year":"2006","journal-title":"Cancer Lett."},{"key":"10.1016\/j.tranon.2020.100926_bib0055","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-14-783","article-title":"FTY720 inhibits proliferation and epithelial-mesenchymal transition in cholangiocarcinoma by inactivating STAT3 signaling","volume":"14","author":"Lu","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0056","doi-asserted-by":"crossref","first-page":"10707","DOI":"10.1007\/s13277-014-2386-y","article-title":"FTY720 reduces migration and invasion of human glioblastoma cell lines via inhibiting the PI3K\/AKT\/mTOR\/p70S6K signaling pathway","volume":"35","author":"Zhang","year":"2014","journal-title":"Tumor Biol."},{"key":"10.1016\/j.tranon.2020.100926_bib0057","doi-asserted-by":"crossref","first-page":"8458","DOI":"10.1158\/1078-0432.CCR-05-0447","article-title":"FTY720: a promising agent for treatment of metastatic hepatocellular carcinoma","volume":"11","author":"Lee","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0058","article-title":"FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.tranon.2020.100926_bib0059","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.6061\/clinics\/2013(07)21","article-title":"FTY720 induces apoptosis in B16F10-NEX2 murine melanoma cells, limits metastatic development in vivo, and modulates the immune system","volume":"68","author":"Pereira","year":"2013","journal-title":"Clinics (Sao Paulo)"},{"key":"10.1016\/j.tranon.2020.100926_bib0060","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.cell.2016.12.022","article-title":"Systemic immunity is required for effective cancer immunotherapy","volume":"168","author":"Spitzer","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.tranon.2020.100926_bib0061","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1002\/1878-0261.12533","article-title":"The identification of a TNBC liver metastasis gene signature by sequential CTC-xenograft modeling","volume":"13","author":"Vishnoi","year":"2019","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11020-3","article-title":"Uncovering the signaling landscape controlling breast cancer cell migration identifies novel metastasis driver genes","volume":"10","author":"Koedoot","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tranon.2020.100926_bib0063","article-title":"Organotropism: new insights into molecular mechanisms of breast cancer metastasis","volume":"2","author":"Chen","year":"2018","journal-title":"NPJ Precis. Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0064","doi-asserted-by":"crossref","first-page":"290","DOI":"10.4149\/neo_2013_038","article-title":"Distant metastasis in triple-negative breast cancer","volume":"60","author":"Tseng","year":"2013","journal-title":"Neoplasma"},{"key":"10.1016\/j.tranon.2020.100926_bib0065","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1158\/1078-0432.CCR-15-2618","article-title":"The sphingosine-1-phosphate modulator FTY720 targets multiple myeloma via the CXCR4\/CXCL12 pathway","volume":"23","author":"Beider","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tranon.2020.100926_bib0066","first-page":"1211","article-title":"Identification of gene expression patterns crucially involved in experimental autoimmune encephalomyelitis and multiple sclerosis","volume":"9","author":"Herrmann","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.tranon.2020.100926_bib0067","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.toxlet.2018.04.008","article-title":"Fingolimod interrupts the cross talk between estrogen metabolism and sphingolipid metabolism within prostate cancer cells","volume":"291","author":"Allam","year":"2018","journal-title":"Toxicol. Lett."},{"key":"10.1016\/j.tranon.2020.100926_bib0068","first-page":"275","article-title":"Improved prognosis of low baseline neutrophil-to-lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes","volume":"10","author":"Fujimoto","year":"2019","journal-title":"Mol. Clin. Oncol."},{"key":"10.1016\/j.tranon.2020.100926_bib0069","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s12885-017-3498-8","article-title":"Lymphocyte count or percentage: which can better predict the prognosis of advanced cancer patients following palliative care?","volume":"17","author":"Zhao","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0070","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/2051-1426-2-3","article-title":"Mechanism of tumor rejection with doublets of CTLA-4, PD-1\/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment","volume":"2","author":"Spranger","year":"2014","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.tranon.2020.100926_bib0071","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1124\/dmd.113.056770","article-title":"Translational pharmacokinetic modeling of fingolimod (FTY720) as a paradigm compound subject to sphingosine kinase-mediated phosphorylation","volume":"42","author":"Snelder","year":"2014","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.tranon.2020.100926_bib0072","doi-asserted-by":"crossref","first-page":"565","DOI":"10.4155\/bio-2016-0308","article-title":"Incurred sample reanalysis of fingolimod and fingolimod phosphate in blood: stability evaluation and application to a rat pharmacokinetic study","volume":"9","author":"Nirogi","year":"2017","journal-title":"Bioanalysis"},{"key":"10.1016\/j.tranon.2020.100926_bib0073","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1177\/0091270004264165","article-title":"Multiple-Dose FTY720: tolerability, pharmacokinetics, and lymphocyte responses in healthy subjects","volume":"44","author":"Kovarik","year":"2004","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.tranon.2020.100926_bib0074","unstructured":"Center for Drug Evaluation and Research [CDER]. Application number: 22-527. Clinical pharmacology and biopharmaceutics review(s) [online]. Available from URL: http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2010\/022527Orig1s000clinpharmr.pdf [Accessed 2020 Nov 8] n.d."},{"key":"10.1016\/j.tranon.2020.100926_bib0075","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.2147\/IJN.S156328","article-title":"Targeted co-delivery of Beclin 1 siRNA and FTY720 to hepatocellular carcinoma by calcium phosphate nanoparticles for enhanced anticancer efficacy","volume":"13","author":"Wu","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.tranon.2020.100926_bib0076","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2020.100926_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105140","article-title":"In vivo antitumour properties of tribenzyltin carboxylates in a 4T1 murine metastatic mammary tumour model: enhanced efficacy by PLGA nanoparticles","volume":"142","author":"Anasamy","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.tranon.2020.100926_bib0078","doi-asserted-by":"crossref","first-page":"14854","DOI":"10.1039\/C5NR03693C","article-title":"Near infrared light-actuated gold nanorods with cisplatin-polypeptide wrapping for targeted therapy of triple negative breast cancer","volume":"7","author":"Feng","year":"2015","journal-title":"Nanoscale"},{"key":"10.1016\/j.tranon.2020.100926_bib0079","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/cen3.12397","article-title":"Neurological safety of fingolimod: an updated review","volume":"8","author":"Yoshii","year":"2017","journal-title":"Clin. Exp. Neuroimmunol."},{"key":"10.1016\/j.tranon.2020.100926_bib0080","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/oncsis.2015.16","article-title":"The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ER\u03b1 expression and enhances hormonal therapy for breast cancer","volume":"4","author":"Hait","year":"2015","journal-title":"Oncogenesis"}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320304186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523320304186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T14:46:43Z","timestamp":1761835603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523320304186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1936523320304186"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100926","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of Fingolimod in triple negative breast cancer preclinical models","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2020.100926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100926"}}